Full Year Report January – December 2018
BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolioOctober – December 2018 · Net revenues for the period amounted to SEK 515.3 million (51.0) · Operating profit amounted to SEK 430.3 million (14.7) · Profit for the period amounted to SEK 335.2 million (11.8) · Earnings per share were SEK 3.81 (0.16) · Cash flow from operating activities amounted to SEK -89.3 million (-45.7) January – December 2018 · Net revenues for the period amounted to SEK 714.0 million (140.7) ·